Hematology and Oncology Book



Small Molecule Inhibitor-Mediated Chemotherapy

Aka: Small Molecule Inhibitor-Mediated Chemotherapy
  1. See Also
    1. Targeted Cancer Therapy
    2. Monoclonal Antibody-Mediated Chemotherapy
    3. Immune Checkpoint Inhibitor
    4. CAR T-Cell Therapy
    5. Chemotherapy
  2. Mechanism
    1. Targeted to Tyrosine Kinases, interfering with EGFR, HER2-neu and VEGF
    2. Small molecules that principally act intracellularly
    3. Less specific than monoclonal antibodies
  3. Pharmacokinetics
    1. Oral agents
    2. Very short half life (hours)
  4. Advantages
    1. Much less expensive than monoclonal antibodies
  5. Drug Interactions
    1. Multiple related to Cytochrome P450 enzymes
  6. Agents
    1. Bortezomib (Velcade)
    2. Dasatinib (Sprycel)
    3. Erlotinib (Tarceva)
    4. Gefitinib (Iressa)
    5. Imatinib (Gleevec)
    6. Lapatinib (Tykerb)
    7. Sorafenib (Nexavar)
    8. Sunitinib (Sutent)
  7. References
    1. Imai (2006) Nat Rev Cancer 6:714-27 [PubMed]

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree